DCLK1 and head and neck squamous cell carcinoma: The recent development of a potent and highly specific DCLK1 inhibitor (69) suggests that both targets can be optimally exploited for the treatment of patients with HNSCC and other cancers driven by DCLK1 and NOTCH pathway alterations.